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ABSTRACT 
Background: Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is a chronic 
debilitating condition characterized by physical and mental fatigue with a heightened 
sensitivity to exertion. To date, the causes are unknown. However, recently the condition has 
been implicated as a chronic sickness behavior state. That is, the adaptive changes in brain 
and behavior commonly following acute infection (experiences of malaise, fatigue, brain fog 
and so forth) seem to have become chronic and thus maladaptive, since no infectious agent is 
present. The condition is often debilitating, but no effective treatments are available, which 
implies that interventions are normally aimed at reducing symptoms and/or restoring or 
improving functioning. Furthermore, classifications are multiple and not empirically based. 
As such, there is a need for: (1) empirical investigations of how symptoms present and relate 
to each other and other measures of clinical importance; (2) evaluations of behavior medicine 
treatment approaches aimed at improving functioning and quality of life, and; (3) studies 
investigating sickness behavior processes in ME/CFS on both subjective and objective levels. 
Aims: The overarching aims of the present thesis were to: (a) investigate factors of importance 
in ME/CFS, including; (b) symptom patterns and their relationships to health and functioning 
(Study I); (c) inflammatory markers implicated in sickness behavior and fatigue and their 
associations with common symptoms (Study III); (d) the level of subjective sickness behavior 
in ME/CFS, compared to chronic pain, primary care patients and the general population (Study 
IV), and; (e) evaluate the acceptability, safety and preliminary efficacy of an Acceptance and 
Commitment Therapy(ACT)-based behavior medicine treatment protocol aimed at increasing 
functioning and quality of life in ME/CFS (Study II). 
Methods: All ME/CFS patients in the four studies were included after referral and diagnostic 
assessment (CDC and CCC or ICC criteria) at a tertiary specialist clinic. In Study I (n=106), a 
total of 14 common ME/CFS symptoms were quantified and latent symptom subgroups were 
explored. The relationship between latent symptom subgroups and measures of health and 
functioning were investigated. In Study II (n=40), the effects of the ACT treatment on measures 
of disability, symptoms and health-related functioning were investigated. In Study III (n=53), 
associations between inflammatory markers and common symptoms in ME/CFS were 
investigated. In Study IV, levels of subjective sickness behavior were investigated in, and 
compared between: patients with ME/CFS (n=40); patients with chronic pain (n=193); patients 
in primary care (n=168), and; individuals from the general population (n=163). The 
  
associations between sickness behavior and self-rated health, mental and physical health-
related functioning were also explored.  
Results: The results in Study I showed four distinct subgroups in which differentiated 
symptoms gathered representing inflammatory, pain, neurocognitive and autonomic symptoms 
respectively. The symptom subgroups overall showed significant correlations with important 
clinical measures, although rarely exceeding .50, indicating the importance of other factors. 
ACT-based behavior medicine treatment can be considered acceptable, safe and preliminary 
effective for patients with ME/CFS (Study II). In Study III, several inflammatory markers (β-
NGF; CCL11; CXCL10; IL-7; TGF-β-1 and; TNF-) showed significant associations with 
common symptoms (post-exertional fatigue; impaired cognitive processing; musculoskeletal 
pain, and; recurrent flu-like symptoms). The level of sickness behavior was similar between 
ME/CFS and chronic pain patients, and significantly higher than in patients from primary care 
and individuals from the general population (p’s <.001).  
Conclusions: Symptoms in ME/CFS seem to present in distinct patterns, underlining the 
importance of the further study of symptom but also illness subtypes. However, factors other 
than criteria symptoms, such as experiential avoidance and cognitive fusion, are likely more 
accessible targets in behavior medicine treatment. The results from the ACT-based feasibility 
study indicate the utility of conceptualizing disability in ME/CFS from a modern learning 
theory perspective, and the ACT-based behavior medicine treatment format should be further 
investigated in randomized controlled studies. Finally, sickness behavior processes may guide 
future research in the differentiation of ME/CFS illness subtypes, as indicated by the level of 
subjective sickness behavior reported in ME/CFS which is equal to the level found when 
healthy human subjects are injected with bacterial endotoxin to cause transient sickness 
behavior in an experimental setting. 
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1 INTRODUCTION 
We all know how it feels to be sick. You have a headache, you feel tired and drained, your 
body aches, you definitely feel less smart and quick, you don’t really want to see or hang out 
with anybody. Basically, your body tells you to do nothing, except maybe lie down and watch 
some semi-engaging tv-series until the symptoms have receded. Picture yourself for a second, 
the last time you were sick, and all the symptoms you had and how you felt and what you did. 
And now imagine that the symptoms stay the same, basically every day, for years to come. 
This thesis concerns one of the most debilitating and yet unsolved conditions in healthcare – 
Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). For many with the 
diagnosis, the above description is their everyday reality. I will discuss the history of the 
condition (it is not new but has had many names), how it presents, factors affecting 
functioning and quality of life, how the life’s of the sufferers can be improved, and how the 
intricate interplay between the central nervous system, the immune system and behavior 
could be the key to understand what gives rise to the condition, how it is maintained and how, 
hopefully in the future, it can be resolved.  
 
 
    Stockholm, August 2019.
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2 BACKGROUND 
2.1  MYALGIC ENCEPHALOMYELITIS/CHRONIC FATIGUE SYNDROME 
(ME/CFS) 
2.1.1  Definition, classification and symptoms 
Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is classified as a 
neurological disorder by the World Health Organization (1). However, etiology and 
pathophysiological mechanisms are still unclear and multiple definitions and classification 
systems exist. The condition has been documented in the medical literature since the 
1800’s, it was described and termed “benign Myalgic Encephalomyelitis” in an anonymous 
editorial in The Lancet in 1956 (2). Historically, phenomenological descriptions of the 
conditions we now classify as either ME/CFS or clinical burnout/stress-related exhaustion  
are analogous to the condition termed Neurasthenia, or Nervous Exhaustion, by George 
Beard in 1869 (3). Interestingly, since then, ME/CFS and stress-related exhaustion have 
been researched and clinically treated as two separate phenomena depending on their 
assumed etiologies (immunological vs. psychological stressors), despite the many 
similarities as discussed below (4, 5). However, while attempting to differentiate the 
condition, the name Myalgic (muscle pain) Encephalomyelitis (inflammation of the brain 
and spinal cord) somewhat obscures the difficulties in finding a distinct marker, as the 
prevalence of muscle pain related to inflammation in the brain and the spinal cord in this 
condition is still in need of research support (6). Although numerous studies show 
abnormalities or differences in levels of immune and inflammatory markers in individuals 
diagnosed with ME/CFS compared to healthy controls, results are often unspecific and 
differences are only seen in some individuals (7). Muscle pain is highly prevalent, but not a 
required symptom for making a diagnosis, and thus misleading in describing the whole 
illness population (1, 8-11). Focusing solely on fatigue in naming the condition may also be 
too narrow, given the broad array of symptoms commonly occurring (10-15).  
 
Longstanding unexplained physical and mental fatigue that is not substantially alleviated by 
rest, resulting in significant reductions in functioning is a key feature of most diagnostic 
criteria of the illness. However, patients normally present with a range of additional 
symptoms and diagnostic systems differ in which symptoms should be considered 
mandatory for diagnosis (9). Recently, a systematic review by Brurberg et al. identified 20 
different classification systems used for making the diagnosis of ME/CFS (9). Although 
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new definitions have been developed since, the Centers for Disease Control and Prevention 
(CDC) diagnostic criteria from 1994 (1) (also called the Fukuda criteria) is still the most 
commonly used system in research and clinical settings (9). In contrast, clinicians and 
researchers more recently have suggested the use of the 2003 clinical working case 
definition (11) (also known as the Canadian consensus criteria) and the revised version 
known as the International Consensus Criteria (ICC) from 2011 (10) over the CDC criteria. 
Furthermore, in 2015 the Institute of Medicine suggested a new definition/new name, 
Systemic exertion intolerance disease (SEID) (8).  
The cardinal symptom in these more recent classification systems is the systemic 
hypersensitivity to exertion (termed post-exertional malaise (PEM) or post-exertional 
neuroimmune exhaustion (PENE)) and a prolonged recovery time after exertion. PEM is 
described as the distinct increase of fatigue and/or other symptoms in concurrence with a 
rapid and marked loss of muscular and/or mental energy after even mild or moderate 
physical, cognitive or emotional effort with a prolonged recovery period lasting up to days 
(8, 10, 11). Many researchers and clinicians argue that this feature, rather than longstanding 
fatigue, should be the main and mandatory symptom for diagnosis (8, 10, 11). Although 
this might be a reasonable argument, and highlighting its importance seems adequate, there 
is a need for more research investigating for whom and in what way this feature presents, 
varies and relates to quality of life and functioning (16-19). Importantly, in my opinion, this 
is not a symptom in itself but rather a hypersensitivity to stimuli and/or effort resulting in 
symptom flare that varies broadly in its presentation in patients. As such, multiple 
definitions of this feature exist (20). The evident variability in definitions and symptoms 
gives rise to larger questions, namely, the need for the investigation of illness subtypes, and 
how the condition overlaps and/or distinguishes itself from similar conditions. 
 
For perspective, it is of value to briefly return to the similarities between ME/CFS and 
clinical burnout/stress-related exhaustion, where clinical features overlap to a large extent 
(4, 21). Individuals with stress-related exhaustion normally present with longstanding 
mental and physical fatigue, cognitive difficulties and hypersensitivities to sensory stimuli 
(21). Roughly, the distinguishing differences are (a) how the etiology and pathophysiology 
are conceptualized and; (b) the general trajectory and treatment response of the illness (4, 
21-23). In ME/CFS, since the 1980’s, a viral infection has been described as the common 
specific mark of onset, while in clinical burnout/stress-related exhaustion, longstanding 
work-related psychosocial stress is highlighted as the main contributor to symptom debut 
(4, 5, 23-26). However, a viral infection at the time of illness debut is not a requirement for 
  5 
making a diagnosis of ME/CFS (1, 10, 11). Importantly, not all ME/CFS patients describe 
their illness debut as a direct effect of an infection and many patients describe longstanding 
stressors or stressful life events as precipitating factors (27).  
 
In summary, illness definitions of ME/CFS are multiple and most notably, none are based 
on empirical data of vulnerability factors, biological markers, comorbidities and/or overlap 
with similar conditions, symptom prevalence, intensity or relation to disability but on 
consensus. Hence, there is an evident need for studies investigating which and how 
biological and psychological markers and symptoms co-occur, how they relate to each 
other, and how they relate to disability and the course of the condition. Such steps seem 
crucial in order to develop definitions that allows for a systematic investigation of the 
mechanisms underlying the debilitating symptomatology in ME/CFS, but also in similar 
conditions such as fibromyalgia (FMS), chronic pain, irritable bowel syndrome (IBS) and 
stress-related exhaustion. 
 
2.1.2  Epidemiology – prevalence, incidence and natural course 
ME/CFS affects approximately 0.76-3.28 % of the adult population (28-32). In a 
comprehensive meta-analysis by Johnston et al (33), it is noted that the variation in 
prevalence across studies is plausibly due to differences regarding geographical area, 
method (self-report vs. clinical) and diagnostic criteria. However, to date there are no 
epidemiological studies based on the more recent definitions of the illness. On the basis of 
the small number of cross-cultural studies that exist, prevalence numbers appear to be 
similar across countries and cultures (31-36). 
The illness prevalence differs vastly between the sexes, approximately 70-83 % of 
individuals in clinical and community samples are women (30, 31, 36-38). The largest and 
most robust population-based incidence study by Bakken et al. (39) found that age, with 
two separate incidence peaks (10-19 years of age and 30-39 respectively) and sex (female 
to male rate ratio of 3,2:1) were associated with elevated incidence risk. A recent 
retrospective cohort study showed that gastro-intestinal infection and previous 
psychological disorder independently were related to an elevated risk of subsequent IBS 
and ME/CFS (40). Notably, the sex prevalence characteristics of ME/CFS are similar to 
conditions such as chronic pain, FMS, IBS and most auto-immune illnesses (41-44). 
However, it is not known if women and men are differently affected in ME/CFS, regarding 
for example biological and psychological factors. 
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Studies of the natural course of the illness report small variations in symptoms and 
disability over time if the condition is untreated (29, 45-49). A small proportion of 
individuals seem to improve somewhat in symptom burden, while only a few percent 
demonstrate recovery (27). However, the use of different diagnostic criteria, context 
(community vs. primary or specialist care) and methods of sampling (self-report vs. 
clinician assessed) vary and thus make comparisons of results between studies difficult 
(45).  
The condition often has detrimental effects on daily functioning and quality of life. Recent 
research suggests that health-related quality of life in individuals with ME/CFS is lower 
than other illness populations with well-documented disability (e.g. Multiple Sclerosis, 
cancer, stroke) (50). Furthermore, the high prevalence of mood and anxiety conditions 
(17.2 % and 24.0 % respectively) compared to the general population (5.2 % and 8.8 % 
respectively) is indicative of a severely affected group (51, 52).  
 
2.2 ETIOLOGY AND PATHOPHYSIOLOGICAL MECHANISMS 
Numerous etiological and pathophysiological factors have been suggested since the 1956 
description of the condition in The Lancet (2, 7, 53). Ranging from suggestions of re-
activated viruses and bacteria to arguments for psychological/psychosocial factors, no 
conclusive findings have emerged despite a marked increase in research into illness 
mechanisms during the last 30 years (54). Again, the heterogeneity in patient history of 
stressors before debut, type of illness debut, symptomatology, comorbidities, course and 
disability/severity are plausible explanatory factors for the variability in findings. 
Given the symptomatology and classification, research into potential illness mechanisms 
have mainly focused on the brain and central nervous system and the potential involvement 
of the immune and endocrine systems (7, 55-57). 
 
As in conditions with a similar symptom presentation like chronic pain, IBS and FMS, 
central sensitization has been suggested as one pathophysiological mechanism. In brief, 
central sensitization refers to a maladaptive lowered threshold for (potentially) noxious 
stimulation (pressure, warmth, cold and so forth) with a heightened excitatory mode in 
neurons conveying such signals from the body to the brain (58). Simplified, the body is 
telling the brain that it is in danger (via pain), although no infectious agent, wound or nerve 
damage is present. Such processes are worthy of further investigation in ME/CFS, 
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especially in light of the high prevalence of chronic widespread pain and hyperalgesia in 
ME/CFS, and the principal similarities between central sensitization and the 
hypersensitivity to stimuli and effort characteristic in ME/CFS (PEM) (57, 58). However, 
not all ME/CFS patients presents with pain symptoms, limiting the full explanatory value of 
this theory. Studies investigating potential abnormalities in the function of the 
hypothalamic-pituitary-adrenal (HPA)-axis have not found any evident dysfunction that 
would explain the clinical presentation (59). While some results indicate differences 
between patients and healthy controls, for example a mild hypocortisolism in some patient 
populations, other studies do not find such differences (60). Also, subtle changes in the 
HPA function may be secondary to the illness state itself (59). This is echoed in the field of 
immune research on ME/CFS, where findings of differences in immunological and 
inflammatory markers are as prevalent as results showing no differences (7, 54, 61). 
However, this would be less confounding if the illness drivers are differentially distributed, 
where brain-immune interactions play an important role for symptom development in a 
subset of patients. 
 
2.2.1 Psychoneuroimmunology and sickness behavior 
The interactions between the immune, endocrine and central nervous system might provide 
some keys to the understanding of ME/CFS. With immune system activation, inflammatory 
mediators (cytokines) are released (62). These small proteins act both locally and globally 
in the body and are important factors in the initiation, maintenance and resolution of 
inflammation. However, these proteins can also affect the brain via multiple signaling 
pathways, mainly via afferent nerves (most importantly the vagus nerve) or via locations 
where the blood-brain-barrier is weaker (63-66).  
Following the acute release of cytokines, for example due to a viral infection, the individual 
soon presents with sickness behavior which includes fatigue, malaise, anxiety, anhedonia, 
worsened mood, reduced social interaction and increased pain sensitivity (67). Within this 
field of research, the sickness behavior response is not viewed as a sign of weakness, but a 
motivational state intended to promote energy conservation in order to facilitate the 
immune response to pathogens. As such, the sickness behavior state is assumed to be an 
evolutionary response to threats against homeostasis. That is, the experiences (e.g. fatigue) 
and overt behaviors (e.g. social withdrawal) that constitute the sickness behavior response 
are thought to have evolved to promote rest and recovery. In the prototypical situation then, 
sickness behavior is viewed an adaptive response in the short-term by increasing survival 
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from infections. However, these changes are also suggested to contribute to ill-health and 
disability in the long-term, when persisting after recovery or where recovery has not been 
completed (68, 69). 
In the field of psychoneuroimmunology (PNI), these effects of pro- and anti-inflammatory 
mediators on the brain and behavior, and the vice versa effects, are the main foci of 
research (63, 70-72). Although it is beyond the scope of the present thesis, future research 
investigating how and which areas in the brain that may elicit, respond to or forward the 
sickness signals in the sickness behavior circuitry will be of utmost value for the 
development of our understanding of ME/CFS.  
However, there is evident merit in investigating peripheral aspects of sickness behavior as 
they are more easily accessible, for example by investigating inflammatory marker levels in 
blood and subjective experiences. The relationship between cytokine-mediated 
inflammation and the development of fatigue and neurocognitive symptoms have been 
explored in for example cancer-related fatigue (73-75). Although preliminary, the results 
from such studies indicate an association between the variation of inflammatory markers 
and the development of longstanding fatigue and cognitive dysfunction. In Gulf War 
Illness, with a symptom profile similar to ME/CFS and unknown etiology, inflammatory 
markers may be related to the course of fatigue (76). 
The association between inflammatory markers and symptoms has also received support in 
for example mood disorders (77-80), psychosis (81), seasonal allergy (82) and in relation to 
subjective health without demonstrable disease (83). It follows then, that the sickness 
behavior processes can be initiated without an ongoing infection, through administration of 
bacterial endotoxin (with a structure found on the surface of bacteria with highly potent 
immune-stimulatory capacity) or typhoid vaccine (79, 84, 85), by conditioning (86) or by 
stress (87). As such, sickness behavior is of importance also in situations besides the 
prototypical (when due to an ongoing infection). Notably, the increasing body of research 
on the relations between the sickness behavior circuitry and psychological/behavioral 
factors has led to some preliminary but interesting results within the ME/CFS field (88). 
Recent studies investigating the relationships between objective and subjective markers of 
stress and inflammation, depression, stress management skills and symptoms in ME/CFS 
indicate the importance of taking such interactions into account (88-90). Results indicate 
that levels of perceived stress management skills were related to less fatigue and distress 
but also to decreased levels of inflammatory cytokines (90). 
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As previously mentioned, there has been some debate as to which extent psychological 
factors play a role in the illness etiology and/or maintenance. The inherent mind-body-
dualism perspective is an evident problem. Importantly, the developments within the field 
of psychoneuroimmunology makes debate regarding the mind or the body as the “cause” of 
symptoms and disability obsolete, with a growing body of research showing that 
psychological factors, stress, inflammation, the brain and behavior affect each other in 
complex ways (91). More so, the importance of psychological factors for how the illness 
affects functioning and quality of life is presumably as important as in other longstanding 
somatic conditions (92-97). That is, developing adaptive and long-term effective 
approaches and strategies for illness-related symptoms, emotions and thoughts should be 
crucial in minimizing the illness impact and alleviating suffering. In for example cancer, 
Multiple Sclerosis, Rheumatoid Arthritis, chronic pain, IBS and FMS, addressing 
psychological and behavioral factors beyond the levels of symptoms or inflammation has 
been shown to lead to better health outcomes (97-102).  
 
2.3 TREATMENT – BIOLOGICAL AND BEHAVIORAL PERSPECTIVES 
2.3.1 Treatments for ME/CFS 
 
In ME/CFS, no pharmacological or biological treatments aimed at symptom alleviation 
show evidence of efficacy (103, 104). Studies of B-cell depletion with Rituximab initially 
showed promising results for subsets of patients with ME/CFS, however results from the 
most recent multicenter placebo-controlled trial suggest no evident long-term benefits (105-
108). Importantly, heterogeneity in the patient population could explain such results, and 
future studies should investigate why, how and for whom such immunosuppressive 
strategies may be effective and safe in the long term. Plausibly, auto-immune and/or other 
inflammatory processes are important in some but not all cases of ME/CFS. 
To date however, given the absent conclusive results in medical treatment trials, studies 
investigating the effects of cognitive behavior therapy (CBT) have accumulated the most 
evidence of efficacy (109, 110). Generalizing, CBT-based treatments conceptualize 
disability as related to a non-helpful fear-avoidance cycle, where fear about unwanted 
outcomes (for example symptom exacerbation) give rise to avoidance behaviors (for 
example avoiding situations and activities that may worsen symptoms) that maintain 
symptom levels. The target then, is to break this cycle.  Although it has given rise to much 
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debate and critique from patient organizations, the to-date largest trial comparing CBT to 
graded exercise, adaptive pacing and standard medical treatment showed moderate but 
evident improvements in functioning (111). Importantly, as the authors also highlight, the 
modest number of strongly improved patients may reflect the heterogeneity of the 
population (112). One possible explanation is that treatment responders represent a subtype 
analogous to stress-related exhaustion, where improvements in somatic symptoms 
following multimodal treatment including CBT are more commonly seen (21, 113).  
Overall, CBT-based treatments for ME/CFS vary in foci and scope as well as in underlying 
assumptions of disabling mechanisms. Also, the variation in diagnostic criteria used makes 
conclusions about the efficacy of CBT-based (and biological/pharmacological) treatments 
harder. Some CBT treatment formats focus on symptom alleviation by ways of changing 
illness beliefs and behaviors and thus increasing activity and functioning, while others are 
aimed at managing the symptoms by using skills such as relaxation (110). Hence, central 
targets and outcomes vary, from symptom decrease to increases in quality of life. As long 
as the etiology and pathophysiology of the condition remain unknown, it is equally hard to 
argue for, for example solely immunological or solely psychological mechanisms of 
symptom maintenance in this condition. Importantly, as the sickness behavior circuitry can 
be active even in the absence of pathogens or verifiable disease, behavior medicine 
approaches to longstanding somatic conditions with unknown pathophysiology may also be 
directed at other targets than symptom decrease. Novel developments within the field of 
behavior medicine highlights the importance of developing approaches to symptoms and 
discomfort based on a generic sickness behavior and learning theory model (114).  
 
2.3.2 Analyzing disability from a learning theory perspective 
 
The clinical application of learning theory, functional analysis, may add to the 
understanding of any illness condition, as the analysis focuses on the most accessible 
variables, experiences and behavior (115). From a functional analytic perspective, 
experiences and behaviors should always be analyzed and understood in a context. This 
includes identifying relevant antecedents (for example, perceived signals from the body as 
potential triggers for a behavior), and consequences following the behavior (for example, a 
perceived change in the signal from the body as a potential reinforcer for a behavior). As 
such, by applying operant conditioning principles (learning by consequences), one can 
investigate which antecedents and consequences that are most relevant in influencing target 
behaviors, in the short and long-term (116). This in turn, may guide the evaluation of the 
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efficacy of behaviors/strategies aimed at for example reducing symptoms or improving 
quality of life. Importantly, the model makes sense of avoidance approaches to 
symptoms/discomfort, as the immediate alleviation of such experiences is a most powerful, 
and plausibly inherent evolutionary, reinforcer for behaviors (117). The analysis of long-
term effects of such strategies is then applied for evaluating the efficacy or inefficacy of the 
alleviation of discomfort or improvement of life quality over time. As such, the functional 
analysis gives an overview of central (experienced) problems and contrasts them to long-
term wanted consequences/goals, and guides the formation of treatment target behaviors 
connected to those goals. 
In a learning theory-based behavior medicine treatment approach, educating the patient 
about the evolutionary but unhelpful function of prolonged non-malignant symptoms and 
the behavioral repertoire it triggers is a core intervention. Hence, a shift in perspective, 
from symptom reduction to a valued life, could be a more accessible and effective approach 
in behaviorally oriented treatments for a chronic illness like ME/CFS. In recent years, such 
perspectives in behavior medicine treatment approaches to longstanding somatic conditions 
has received increased attention and support, especially in treatment studies evaluating 
Acceptance and Commitment Therapy (ACT) (114, 118). 
As such, there is evident value in further investigations of the importance of psychological 
factors for the illness severity in ME/CFS, especially in the context of plausible subtypes 
(for example ME/CFS and stress-related exhaustion) on a spectrum where differential 
aspects of psychological factors play a role. Furthermore, the importance of psychological 
and behavioral factors for ME/CFS is clear in the context of the general human processes 
suggested to contribute to suffering and disability as they are defined by novel 
developments within learning theory and its clinical application - Relational Frame Theory 
(RFT) and ACT (118, 119). 
2.3.3 A contextual behavioral approach to human suffering – Relational 
Frame Theory and Acceptance & Commitment Therapy 
2.3.3.1 Relational Frame Theory – a functional analytic account of human language and 
cognition 
 
RFT is a functional analytic theory of human cognition, language and behavior developed 
within the broader research field of contextual behavioral science (115). It is beyond the 
scope of this thesis to give an in-depth description of RFT (and ACT), and the interested 
reader is recommended the excellent introductions by Törneke and Hayes et al. respectively 
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(118, 120). In short however, RFT suggests that the human capability to think abstractly – 
to analyze and solve problems, compare the present with an imagined future, evaluate a 
novel experience based on prior experiences and so forth –is intertwined with the 
development of language and the ability to interpret and take actions that are not based only 
on the worlds formal characteristics (what it looks like, e.g. warm/cold; light/dark etc.) but 
rather on what it means in the given context based on arbitrary symbolic, or language-
derived, characteristics. For example, “life has no meaning” is a statement we all can 
understand as meaning something, and may make us behave in certain ways if we believe 
the statement, even though we cannot observe it in the same way we observe and react to 
warm temperature.  
 
Building on respondent and operant learning theory, what RFT adds is a model to help 
understand how this complex human behavior – cognition – affects how conditioning 
fundamentally works for humans. Our language provides an ability to relate anything to 
anything along all imaginable dimensions (for example “better”, “worse”, “nicer” and so 
forth - try to come up with arguments for why a banana is “better” than a car - you will 
succeed!). This ability becomes more advanced as a function of age, learning and brain 
development (119). Through learning, it is developed via multiple exemplar training from 
once we become able to use language, where the reinforcer for the behavior is basically that 
it makes sense, that we are understood. The perhaps most important effect of this ability is 
the constant process of transformations of stimulus functions that follows.  
Simplified, the stimulus functions are the cues and qualities we consciously and non-
consciously act on to choose behavior in a given situation. That is, our ability to evaluate 
and respond in a certain situation are not only based on the formal characteristics of the 
situation (warm weather, blue skies) but dependent on the arbitrary, language-derived 
characteristics based on our knowledge and previous experience of, to us, related situations 
(“but winter is coming”).  
 
With the ability to understand the world based on arbitrary symbolic (language) meaning, 
this ability and the processes it entails are always going to affect how we experience and act 
in the present situation. A simplified example to clarify: The first time I play tennis, what 
shows up in my mind and body and how I behave will be very different from the ten 
thousandth time I play. It will be different, even though the weather, time of day, my shoes, 
the court, racquet, balls and opponent have the exact same formal characteristics as the first 
time. When I hit the ball the ten thousandth time, it is not only the velocity and angle of the 
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ball coming towards me (and my rising fear) that affects how I hit it back, but also my 
history of all similar angles and velocities as well as my evaluation of my opponents earlier 
and current status via multiple dimensions (“it’s been a long game, he’s more tired now 
and I know he sprained his ankle last month so he’ll be cautious – I’ll try a drop shot!” and 
so forth and so on). Such complex behavior is not explained solely by respondent or 
operant principles (this is the first time I’ve played somebody with a sprained ankle). The 
stimulus functions and cues for behavior in the situation are derived through the situations 
relationship to all things related to such situation in the network that is my unique learning 
history.  
 
This ability is certainly crucial for the excellence of human development in all domains of 
life. Not in the least, it simplifies everyday behavior, as we as humans through language 
can develop and follow general rules (e.g. “being kind is good!”) to adapt our behavior 
instead of behaving as a two-year-old across the whole lifespan (121). The possibility of 
acting on the present situation in the light of one’s experience and ability to “see” possible 
consequences in the future has been and is an evident evolutionary advantage for the human 
race (122). The dark side however, is the potential for humans to be in contact with 
experiences that elicits discomfort and avoidance behaviors, without long-term discomfort 
resolution, at every waking moment.  
This, since everything (situations, objects, sights, sounds, smells, thoughts, memories, 
feelings, bodily sensations) can (/will) be related to, and evaluated in relation to, everything 
else in my learning history and the present situation. For example, even the word “pain”, or 
the thought of pain, shares some qualities with the actual experience of pain, and will then 
more likely be avoided through the same rule-governance that has helped me avoid real 
pain (123). Things we experience in our mind however, do not seem to go away by trying 
to avoid them, but rather quite the opposite. Try, for 30 seconds, actively with focus, not to 
think about something painful you’ve experienced in your life. It’s not that easy. 
 
As language-able humans, we do not only learn through respondent (association) or operant 
(by consequences) processes, but mainly by this derived conditioning. That is, we don’t 
have to have experienced something first-hand as horrible, we can expertly start to avoid it 
for the rest of our lives through language-based derivation and the following transformation 
of stimulus functions. According to RFT, behaviors in everyday life are almost exclusively 
dependent on this symbolic logical system where we explicitly and implicitly consider 
experiences (for example symptoms, feelings and thoughts) to be causes for behaviors. This 
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in turn, may result in behavioral patterns defined by avoidance observable on the “outside” 
(for example avoiding close relationships) because of the “inside” (for example “I could 
never stand the hurt of being left”). RFT gives an account of how and why we as humans 
seem prone to act based on these indirect, language-created functions of a stimulus, instead 
of looking for other more adaptive ways to approach, for example, discomfort. Simply put, 
we do it because it is logically coherent in our symbolic world – it makes perfect sense.  
 
These processes become highly relevant when internal bodily signals from the evolutionary 
older homeostatic systems (stress/fear and sickness behavior responses for example) are 
processed through our newer symbolic interpretation system (for example the thought 
“something is wrong and needs to be fixed!”). In the presence of discomfort of symptoms, 
the interpretation of these signals may give rise to thoughts and behaviors aimed at 
resolving this discomfort as an evolutionary function (122). However, focusing solely on 
symptom resolution in a condition where no pathophysiological process is known and 
hence without evident markers and mechanisms to target, could potentially establish rules 
and behaviors that paradoxically only will produce more discomfort and suffering. The 
thought/rule “I can’t continue to live my life until I get well” is an understandable one from 
a sickness behavior motivational state, but totally unhelpful in a longstanding condition 
where no effective resolving treatment exists. Rather, it presumably results in a life that is 
put on hold, which then only adds to the discomfort, since struggling with aversive 
experiences (symptoms, feelings, thoughts) rarely is part of the valued life for most 
humans. As an alternative to struggling with symptoms and related thoughts and feelings 
that cannot be avoided in the long-term, the clinical extension of RFT – ACT, takes a 
different stance. 
2.3.3.2 Acceptance & Commitment Therapy 
 
In ACT treatment, the overarching aims do not entail symptom or discomfort removal. 
Rather, the aim in treatment is to increase functioning and quality of life by increasing the 
individual’s psychological flexibility. Psychological flexibility in short, is the ability to act 
in line with long-term values (regarding for example relationships, interests, health and so 
forth) even in the presence of discomfort (symptoms, emotions, thoughts) (124). Hence, the 
target in ACT treatment is also to decrease the unwillingness to experience negative private 
events, broadly defined as experiential avoidance. Experiential avoidance is considered to 
predict behaviors aimed at alleviating distress in the short-term. Conceptually this is similar 
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to the sickness behavior motivational state where an avoidance behavioral repertoire is 
activated and evolutionarily adaptive in the acute phase of illness. In chronic conditions 
however, the outcome of such strategies in the long-term is seldom symptom or discomfort 
alleviation. Rather, the effect of experiential avoidance over time is the narrowing of life 
while symptoms and discomfort remain present.  
 
The overall aim in ACT then, is to identify such processes (derived rule-governed behavior 
that continues because of logic coherence despite not resulting in what the rule “says” it 
should) as unhelpful. This identification is termed cognitive defusion. The purpose of this 
analysis is to enable a shift in perspective and behaviors towards a broad and meaningful 
life while making space for the discomfort (acceptance) one cannot remove (118). As such, 
by approaching situations and experiences in new more workable ways, the process of 
transformation of stimulus functions is used in the service of something good. Through 
values-directed behavior change and exposure to stimuli that previously elicited only 
discomfort and avoidance, the qualities of these stimuli are widened and added to. In 
parallel, the individual’s behavioral repertoire is widened and added to, resulting in an 
increase of available ways to act in the presence of discomfort. In essence, psychological 
flexibility is increased.   
In similar conditions like chronic pain, IBS and FMS, psychological flexibility seems to be 
a factor of central importance for the relationship between illness factors and functioning 
and quality of life (98, 125, 126). Consistent with this, treatments aimed at increasing 
psychological flexibility show promising results in these conditions (98, 100, 126-128) 
Although only a few studies exist, acceptance and psychological flexibility seem to be of 
similar importance also in ME/CFS (129-132). However, there is a lack of clinical trials 
investigating if an ACT-based behavior medicine treatment could be of benefit for 
individuals with ME/CFS. 
 
2.4 SUMMARY 
In a chronic illness with unknown pathogenesis and multiple definitions like ME/CFS, one 
main task at-hand should be to identify factors that can effectively be addressed in 
treatment in order to alleviate suffering. Traditionally, in the field of ME/CFS, research has 
to an important extent addressed biological and psychological mechanisms as separate 
domains. From a joint PNI/sickness behavior and behavior medicine perspective, these 
should be bridged in order to develop the knowledge about the mechanisms establishing 
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and maintaining the condition and its effects on behavior and everyday life. Most 
importantly, it is plausible that the symptom complex that constitutes ME/CFS is driven by 
differential factors across the illness population. The identification of illness subtypes may 
be the most promising way to move forward. To investigate how symptom development 
relates to both biological and psychological factors, in which subsets of individuals, and 
how all of the above relate to functioning and quality of life is critical for further 
development of treatments and the understanding of this complex and debilitating 
condition.
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3 AIMS OF THE THESIS 
The specific aims of this thesis were to: 
1. Investigate symptom prevalence and latent symptom patterns in adult patients with 
ME/CFS referred to a tertiary specialist clinic, and examine the relations between latent 
symptom subgroups and: dimensions of fatigue; depression; anxiety; physical and 
mental health-related functioning, and; quality of life. (Study I) 
 
2. Evaluate the feasibility, including acceptability, safety and preliminary efficacy, of an 
ACT-based behavior medicine treatment protocol for adult patients with ME/CFS 
referred to a tertiary specialist clinic. (Study II) 
 
3. Investigate the associations between levels  of inflammatory markers previously related 
to: (a) sickness behavior, and; (b) fatigue severity in ME/CFS respectively, and (c) 
levels of common symptoms in adult patients with ME/CFS referred to a tertiary 
specialist clinic. (Study III) 
 
4. Investigate: (a) the level of subjective sickness behavior, assessed with a validated 
instrument, in  patients with ME/CFS referred to a tertiary specialist clinic; (b) 
differences and similarities in levels of sickness behavior in patients with ME/CFS and 
patients with chronic pain referred to a tertiary specialist clinic compared to patients in 
primary care and individuals from the general population, and; (c) the relationship 
between sickness behavior and self-rated health, physical and mental functioning 
respectively in patients with ME/CFS, patients with chronic pain and individuals from 
the general population (Study IV) 
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4 EMPIRICAL STUDIES 
The studies included in the present thesis are all conducted on clinical samples of adult 
patients with ME/CFS. First, I describe how we explored and identified the presence of latent 
subgroups of symptoms in ME/CFS, and the associations between these symptom subgroups 
and different aspects of health and functioning (Study I). Second, I delineate how we 
developed and evaluated an ACT-based behavior medicine treatment protocol for ME/CFS 
(Study II). Third, I depict how we explored the associations between inflammatory markers, 
measured in peripheral blood, and common/sickness behavior-related symptoms in ME/CFS 
(Study III). Finally, I outline how we investigated and compared the subjective level of 
sickness behavior in ME/CFS with the level in patients with chronic pain, patients from 
primary care and individuals from the general population (Study IV).  
As the methods and results are thoroughly described in the respective paper, I will present 
them here in a briefer format. 
4.1 STUDY I: IDENTIFYING SYMPTOM SUBGROUPS IN PATIENTS WITH 
ME/CFS – RELATIONSHIPS TO FUNCTIONING AND QUALITY OF LIFE 
Symptoms required for diagnosis differ across the different consensus-based diagnostic 
criteria used for diagnosing ME/CFS. Hence there is a need for empirical studies 
investigating if and how commonly reported symptoms present and relate to each other and 
clinically important factors.  
4.1.1 Methods 
Recruitment of patients was part of the diagnostic assessment at an out-patient ME/CFS 
specialist clinic between 2011 and 2013. After diagnostic evaluations by a physician and 
psychologist respectively, a total of 106 adult patients were included in the study after 
fulfilling the 1994 CDC and 2003 Canadian criteria for ME/CFS (1, 11). Dimensions of 
fatigue (MFI-20), depression/anxiety (HADS), health-related functioning (SF-36) and quality 
of life (EQ-5D) were assessed with validated questionnaires (133-136). For the exploration of 
latent symptom subgroups, patients reported the prevalence and intensity (from “not present” 
to “unbearable”) of 14 commonly reported symptoms chosen based on the 2003 Canadian 
criteria and our clinical experience of commonly occurring symptoms (11). Principal 
component analyses (PCA) were utilized to explore how symptoms were related in 
subgroups, bivariate correlation analyses were used to investigate the relationships between 
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symptom subgroups and: dimensions of fatigue; depression; anxiety; health-related physical 
and mental functioning and; quality of life respectively. 
4.1.2 Results 
Main findings include the identification of four distinct and clinically meaningful subgroups 
of symptoms, termed “Inflammatory”, “Pain”, “Neurocognitive” and “Autonomic” based on 
the included symptoms in each group. Furthermore, symptom subgroups were consistently 
related to measures of fatigue, anxiety, health-related functioning and quality of life. Notably, 
the strength of the correlations seldom exceeded .50, which indicates that factors besides the 
common symptoms are important for functioning and health in ME/CFS. 
4.2 STUDY II: ACCEPTANCE & COMMITMENT THERAPY FOR ME/CFS 
(CHRONIC FATIGUE SYNDROME) – A FEASIBILITY STUDY 
Based on the findings from Study I, and our clinical and research experience of the chronic 
pain patient population, we sought to adapt and develop our ACT-based behavior medicine 
treatment protocol, developed originally for chronic pain, for patients with ME/CFS. The aim 
was to preliminarily evaluate if the treatment was feasible, accepted as safe and relevant for 
patients, and effective in improving subjective functioning and quality of life. A secondary 
aim was to preliminarily explore the importance of psychological flexibility for the treatment 
outcome. 
4.2.1 Methods 
Adult patients were consecutively recruited after diagnostic assessment at a tertiary specialist 
clinic. Besides fulfilling the 1994 CDC and 2003 Canadian criteria for ME/CFS (1, 11), 
inclusion criteria included no present primary condition (psychiatric or somatic) in need of 
treatment and no other planned treatment in the coming six months. A total of 40 patients 
were included in the study and started treatment consecutively, consisting of 13 sessions (45 
min) weekly to bi-weekly, delivered by a psychologist (10 sessions) and a physician (3 
sessions). The ACT treatment format was developed as an adapted version of a treatment 
protocol developed and evaluated for chronic pain by our group during the last 15 years (98, 
126, 127, 137-144). The treatment is described in more detail in the paper, a brief overview 
will follow here.  
The initial phase of treatment included education in plausible physiological mechanisms and 
learning theory principles. This in order to validate the symptoms as real and at the same time 
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non-malignant, and to shift focus to the function (what do you do in the presence of 
symptoms/discomfort and is it effective?) and not the shape/form/logic of experiences 
(symptoms, thoughts, feelings) and behaviors. In this phase, a functional contextual analysis 
of the present life situation was carried out, identifying all forms of discomfort the patient 
currently struggled with. In the next phase, the “struggle” behaviors and accompanying 
rules/thoughts were operationalized and analyzed based on their workability, i.e. what effects 
they had on either symptom resolution or quality of life. All such strategies and outcomes 
were evaluated in relation to the life the individual valued, concerning for example 
relationships, interests and so forth. The main targets of treatment then, were to increase 
contact with such values as consequences, through increasing values-directed behaviors. The 
practice in identifying and reducing unhelpful rules and behaviors (cognitive defusion) and 
the letting go of the struggle with discomfort that cannot be avoided (exposure and 
acceptance in order to allow a shift in focus towards values) were central parts of sessions 
throughout treatment following the initial education phase. 
Measures of symptoms (measured as in Study I), dimensions of fatigue (MFI-20), 
depression/anxiety (HADS), psychological flexibility (an adapted version of the 
Psychological Inflexibility in Pain Scale replacing Pain with Fatigue), disability (an adapted 
version of the Pain Disability Index replacing Pain with ME/CFS symptoms), health-related 
functioning (SF-36) and quality of life (EQ-5D) were assessed at baseline, post-treatment and 
at 3- and 6-month follow-ups. Additionally, psychological flexibility and disability were 
assessed at mid-treatment in order to enable a preliminary investigation of the importance of 
changes in psychological flexibility for treatment outcome. Changes in all above measures 
across time were analyzed with piecewise (pre-post; post-FU) linear mixed-effects models. 
Furthermore, the participants experience of the treatment format, content, and potential side-
effects, were assessed with a brief questionnaire, developed for the study, after completion of 
treatment. 
4.2.2 Results 
32 patients (80%) completed treatment. Results showed that the ACT-based behavior 
medicine protocol could be considered safe, acceptable and preliminarily effective with 
improvements in multiple outcomes including disability (d=.80) and psychological flexibility 
(d=1.07). In addition, the results indicate that changes in psychological flexibility added to 
the treatment effect on disability in a significant way (p<.001). 
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4.3 STUDY III: THE ROLE OF LOW-GRADE INFLAMMATION IN ME/CFS 
(CHRONIC FATIGUE SYNDROME) – ASSOCIATIONS WITH SYMPTOMS 
As demonstrated in Study I and II, ME/CFS patients present with several symptoms besides 
fatigue, that are consequently related to functioning and health. The symptomatology shows 
great similarities with sickness behavior, the motivational state accompanying innate immune 
activation. In addition, recent research results indicate an association between fatigue severity 
and levels of inflammatory markers. However, there is a lack of studies investigating the 
associations between; (a) sickness behavior-related symptoms; (b) common ME/CFS 
symptoms besides fatigue, and; (c) inflammatory markers previously shown to be related to 
sickness behavior and fatigue respectively. 
4.3.1 Methods 
Adult patients were recruited consecutively after diagnostic assessment a tertiary specialist 
clinic as in Study II. In total, 53 patients were included in this study. Patients rated the 
average severity of symptoms (0-10) during a structured clinical interview. Symptoms 
(recurrent flu-like symptoms; musculoskeletal pain; impaired cognitive processing; post-
exertional fatigue) were chosen based on previous research of sickness behavior and ME/CFS 
respectively and our clinical experience of patient-reported commonly occurring debilitating 
symptoms. Blood was collected in the morning (participants were instructed not to eat before 
blood sampling on this day), plasma was analyzed using the Olink Proseek Multiplex 
Inflammation Panel and the BioRad Human Cytokine Type 1 assay. The Olink panel includes 
92 inflammation-related biomarkers. The BioRad assay was used to measure tumor necrosis 
factor (TNF)-α as this marker was not detectable in approximately 50% of samples using the 
Olink panel. In total, 13 inflammatory markers were chosen for subsequent analyses based on 
previous research of sickness behavior (TNF-α, interleukins (IL)-6 and (IL)-8) and ME/CFS 
(IL-7, IL-10, IL-18, Eotaxin (CCL11), C-X-C motif chemokine (CXCL)1, CXCL10, 
Latency-associated peptide transforming growth factor beta (LAP-TGF-β)-1, Transforming 
growth factor (TGF)-α, Stem cell factor (SCF) and Beta-nerve growth factor (β-NGF)). 
Associations between symptoms and inflammatory markers were investigated with bivariate 
correlations and moderated regression analyses with biological sex as moderator. 
4.3.2 Results 
Several inflammatory markers (β-NGF, CCL11, CXCL10, IL-7, TGF-β-1) showed 
significant associations with post-exertional fatigue, musculoskeletal pain and impaired 
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cognitive processing, and the sickness behavior-related marker TNF- showed a significant 
association with recurrent flu-like symptoms. Furthermore, biological sex moderated some of 
these associations. 
4.4 STUDY IV: SICKNESS BEHAVIOR, SELF-RATED HEALTH AND 
FUNCTIONING – DIFFERENCES IN ME/CFS AND CHRONIC PAIN 
COMPARED TO PRIMARY CARE PATIENTS AND THE GENERAL 
POPULATION 
The overarching context for this thesis is the investigation of ME/CFS from a joint sickness 
behavior and behavior medicine perspective. Notably, the level of sickness behavior, assessed 
with a validated instrument, has not been investigated in patients with ME/CFS nor in 
patients with chronic pain, despite the similarities in symptomatology. Furthermore, we 
wanted to compare the level of sickness behavior in these patient groups with the level in 
patients in primary care and in individuals from the general population, in order to provide 
context for the results. In addition, we sought to investigate the associations between sickness 
behavior, self-rated health and health-related mental and physical functioning in patients with 
ME/CFS, patients with chronic pain and in individuals from the general population. 
4.4.1 Methods 
Patients with ME/CFS (n=40) were recruited as described in Study II and III. Patients with 
chronic pain (n=193) were also recruited at a tertiary specialist clinic, exclusion criteria 
included primary psychiatric comorbidity (high risk of suicide; severe depression; psychotic 
symptoms). Patients at a primary care drop-in clinic (n=168) were recruited consecutively as 
described in detail previously (145, 146). The three most common causes of visit in this 
group were muscle/joint pain, acute infection and airway symptoms (allergy/asthma). Data 
from individuals from the general population (n=163) was collected as part of the 
LongGERD study, investigating abdominal symptoms in a random sample of the general 
population, described previously in detail (147). Sickness behavior was assessed using the 
Sickness Questionnaire (SicknessQ), a 10-item questionnaire developed to assess subjective 
sickness behavior in humans (146). Self-rated health and health-related mental and physical 
functioning were assessed with the RAND SF-36 (ME/CFS and general population)/SF-12 
(chronic pain) Health Survey (134, 148). The first question in the instrument (SF-36/SF-12) 
assesses self-rated health, the mental (MCS) and physical (MCS) composite scores were used 
to assess health-related mental and physical functioning respectively. Linear regression was 
utilized to compare differences in level of sickness behavior between the groups, including 
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item-by-item comparisons. Bivariate correlations and moderated regression analyses were 
used to investigate the associations between sickness behavior, self-rated health and health-
related mental and physical functioning. 
4.4.2 Results 
Patients with ME/CFS and chronic pain reported similar and high levels of sickness behavior. 
The level of sickness behavior was significantly higher in these patients compared to primary 
care patients and individuals from the general population. Significant associations between 
sickness behavior and self-rated health, mental and physical health-related functioning were 
repeatedly shown.  
4.5 ETHICAL CONSIDERATIONS 
All studies in the present thesis have been reviewed by the regional research ethics 
committees in Stockholm or Uppsala. Study 2, 3 and 4 were approved by the board. Study I 
was reviewed but considered a clinical development project which does not fall under the law 
of ethical assessment of research in humans. However, the committee stated no ethical 
conflicts. All participants were given written and oral information and provided informed 
consent. Importantly, all research in the present thesis was conducted in accordance with the 
World Medical Association Declaration of Helsinki (149). The ACT trial was registered in 
the ClinicalTrials.gov registry. All ME/CFS participants in all included studies were referred 
for specialist care, where instructions were that the patient as well as the referring physician 
explicitly stated a request of assessment of ME/CFS and/or ACT-based behavior medicine 
treatment for ME/CFS (if diagnosis had been made by a specialist before referral).  
The present thesis entails an ACT-based behavior medicine treatment study encompassing 
approximately 15 visits á 45 minutes weekly to bi-weekly. Questionnaire data was sampled 
before, during and after treatment as well as at follow-ups. Questionnaire data from ME/CFS 
patients not included in the treatment study was sampled as part of the diagnostic assessment 
visits. The project also includes blood sampling through standard procedure at the hospital by 
trained health-care professionals. 
First, regarding the treatment program, no negative or harmful side effects were considered to 
appear in the short or the long-term. Notably, at the time of study inclusion, ACT had, to our 
knowledge, not been tested for ME/CFS. However, numerous studies investigating the 
acceptability of CBT have not shown any short or long-term negative effects of treatment. 
Furthermore, ACT-based treatment is considered safe and effective for similar conditions 
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(chronic pain, FMS, IBS). More so, the ACT treatment protocol did not entail systematic 
increase in physical activity nor did it by rule encourage participants to systematically push 
their physical limits as a way to improve. Finally, to date there are no empirically evaluated 
or evidence-based treatment programs for patients with ME/CFS in Sweden. Potential 
negative side-effects were continuously monitored throughout the trial. Hence, when 
balancing the risk of negative events with the opportunity of developing evidence-based 
treatments for this severely affected group without any other effective treatment at-hand, the 
treatment program part of the project could be considered ethical as is could potentially lead 
to benefits for the participants, their families and society at-large. 
Second, sampling of blood data was not considered to entail any adverse events for the 
participant in the short or long-term besides the potential momentary discomfort of blood 
drawing. More so, participants were informed that participation in the treatment part of the 
research project was not conditioned on participation in the sampling above and vice versa. 
Furthermore, analyses of the individual data sampled was presented and available to the 
individual participant, which includes tests that are not part of the standard laboratory tests in 
healthcare and hence directly informative for the individual participant. We considered this as 
ethical as the etiology and pathophysiology of the condition is unknown, and discovering as 
well as discarding potential illness mechanisms through this data collection would benefit 
participants both in the short and long-term.  
The identification of a subgroup of patients in which a malfunctioning sickness behavior 
circuitry is a factor in the development of these symptoms has important clinical implications. 
First, this would be a small but important step towards the discovery of disease mechanisms. 
This would also generate specific hypotheses to guide future treatment studies. Furthering the 
knowledge of the diagnosis in this manner would entail the future identification of other 
clinically important subgroups within the patient population. Especially since heterogeneity 
within the patient group is a clear factor that prevents the development of knowledge 
regarding etiology/pathophysiology, reflected in the numerous classifications and lack of 
effective treatment. The results are also expected to significantly contribute to new 
hypotheses regarding the importance of sickness behavior in other long-term intractable 
conditions, such as stress-related exhaustion, chronic pain, fibromyalgia and irritable bowel 
syndrome. Finally, the present research project will generate new hypotheses regarding the 
relationships between sickness behavior and mental health. Etiology and pathophysiology are 
still unknown for many psychiatric conditions, but an increasing number of studies point to 
the link between depression and neuro-immune interactions for example. 
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The questionnaires and data from the studies included in this thesis were coded for anonymity 
and kept safe in locked facilities and secure servers to minimize the risk of violation of integrity. 
Through developing shorter and still valid and reliable instruments, and through achieving 
more effective assessment overall, the patient burden of assessment may ultimately be reduced. 
For the overall project, several parties can be identified for whom the benefits differ. For the 
participants, increased knowledge about ME/CFS and possible comorbidity will potentially 
lead to better care, and possibly fewer unnecessary assessments. Most importantly, the level of 
knowledge of ME/CFS and how it affects health and disability is in general low in the Swedish 
healthcare and health insurance system. Thus, the study participation in research on ME/CFS 
in Swedish samples of patients should also be of value for the participant as it will communicate 
empirically based information about the condition to decision-makers in the proximity of the 
patient as well as to policy makers. For the next-of-kin, increased knowledge about ME/CFS 
may likely lead to less concern (or more adequate concern) in family members and important 
others. Moreover, effective treatments and better assessments will probably also mean less time 
spent in hospitals or clinics for family members and important others. For the healthcare 
system, effective assessment and treatment of patients with ME/CFS probably entails improved 
management of resources e.g. through fewer healthcare contacts and more satisfied patients. 
For the community, savings in terms of reduced costs of healthcare as a result of improved 
assessment and treatment are plausible. 
In summary, it may be concluded that the benefits outweigh the risks associated with the 
research in the present thesis.  
5 DISCUSSION 
5.1 MAIN FINDINGS 
Symptoms other than fatigue that are commonly present in ME/CFS form distinct subgroups. 
That is, symptoms follow patterns where the level of one symptom is related to the level of 
another specific symptom. The symptom subgroups are in turn differentially associated with 
levels of health and functioning in patients with ME/CFS. This might guide future research 
towards the further study of patient subgroups and the identification of accessible treatment 
targets (Study I). Considering the moderate sizes of the correlations it is plausible that other 
factors beyond symptoms, plausibly experiential avoidance and cognitive fusion, are of 
importance for subjective health and functioning in ME/CFS and in need of further study 
(Study I). Consistent with this, targeting these general human processes thought to contribute 
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to suffering and disability as they are conceptualized in ACT treatment was found to be 
feasible, safe, relevant and preliminary effective for ME/CFS patients seeking tertiary 
specialist care (Study II). Sickness behavior-related inflammatory processes may be related to 
symptom intensity in ME/CFS, although larger longitudinal studies are needed to investigate 
causality. The results also indicate the potential importance of investigating biological sex as 
a moderator when studying how inflammatory markers are related to symptoms in ME/CFS, 
where women outnumber men 3:1 approximately (39), as mechanisms may differ between 
the sexes (Study III). The level of sickness behavior as measured subjectively with the 
SicknessQ is remarkably high in ME/CFS, with levels similar to those reported by individuals 
after experimentally induced inflammation (Study IV). This, and the similarity in sickness 
behavior level between ME/CFS and chronic pain patients, clearly indicates the merit of the 
further study of sickness behavior processes in these populations, where both etiological 
factors and important treatment targets could be overlapping. 
5.2 CONCLUSIONS AND LIMITATIONS 
5.2.1 Symptom presentation, variation and heterogeneity in ME/CFS 
The results from Study I expands previous research on symptom patterns in ME/CFS, where 
studies show similarities in findings of latent symptom subgroups pertaining to inflammatory 
(e.g. feverishness), pain (e.g. musculoskeletal pain) and neurocognitive (e.g. difficulties with 
concentration) symptoms respectively (150-152). Notably, we also found a fourth distinct 
subgroup (autonomic) consisting of headache, irritable bowel symptoms and orthostatic 
intolerance (dizziness when standing up). The spectrum of symptoms prevalent in ME/CFS is 
vast, echoed in the multiple illness definitions that have been developed to date (9). Hence, it 
is probable that also other symptoms than those measured in Study I are of importance, which 
is an evident limitation of the study. All of the subgroups found in Study I showed significant 
but differential associations to dimensions of fatigue, depression, anxiety, health-related 
mental and physical functioning and quality of life. The identification of symptom subgroups 
and the variation of the strength of the relationships between these subgroups and important 
clinical measures indicate the importance of the further investigation of: (a) other factors 
important for functioning and quality of life, and; (b) potential illness subtypes. Furthermore, 
my clinical experience of working with this condition is that symptoms, in many cases, vary 
across time not only between but also within patients. This variation is described both in 
terms of the level and type of symptoms. Also, the results from Study IV, where ME/CFS and 
chronic pain patients show great similarities in levels of sickness behavior, indicate potential 
similarities between these groups also with regards to general symptomatology. As such, 
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there is a need for larger longitudinal studies investigating symptom prevalence, intensity and 
variation in ME/CFS, as the cross-sectional design in Study I is a limitation that prevents 
investigation of causality. It would be of evident value to include assessment of similar 
conditions such as chronic pain, fibromyalgia, irritable bowel syndrome and stress-related 
exhaustion in such a longitudinal design, in order to improve classification systems and 
perhaps find better distinguishing features than solely symptomatology and/or perceived 
causes. I think such research is of paramount importance in conditions where etiology and 
pathophysiological mechanisms are unknown, there is a high level of comorbidity (one 
condition may in some cases increase the probability of another), and psychological 
factors/stressors and neuro-immune interactions are plausibly involved.  
5.2.2 The value of ACT for patients with ME/CFS – not a one size fits all 
model 
ACT for ME/CFS (Study II) as described in the study treatment protocol can preliminarily be 
considered safe, with no reported negative effects in the short or long-term, lending further 
support to previous research showing the importance of promoting psychological flexibility 
for lessening the illness impact on functioning and quality of life in ME/CFS (129-132). 
However, there is a need for randomized controlled trials in order to evaluate efficacy. 
Although the drop-out could be considered reasonable (20%), a personal reflection from the 
trial is that ACT for ME/CFS requires therapists that are up-to-date regarding the current 
body of research on ME/CFS in order to maintain the face validity of an ACT approach to 
symptoms and discomfort. Patients with ME/CFS seeking specialist care oftentimes have a 
distinct and coherent story of what their illness is and is caused by, including both school 
medicine and alternative medicine explanatory models. As such, the initial physiological and 
learning theory education part of the treatment (described in detail in the article) making the 
conceptualization of the illness and its impact on life coherent despite unavoidable 
uncertainties, is of crucial importance for enabling the shift in perspective from struggling 
with symptoms to a valued life. This is the case in all ACT treatment, but for clinicians and 
researchers planning similar treatments or studies, it seems even more important to stress in 
ACT for ME/CFS patients, as they have often tried all accessible treatment options. 
Furthermore, the variability in symptom intensity, and most importantly, the hypersensitivity 
to exertion in ME/CFS brings its own set of challenges when conducting an out-patient 
protocol-based trial requiring a certain frequency of face-to-face sessions in the clinic. 
Namely, sometimes patients are too disabled to attend sessions. This is also an evident 
limitation in Study II, where included patients in general had a level of functioning allowing 
the completion of such a format. Patient ratings and our clinical experience from the trial 
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indicate that a more expanded treatment format could be more advantageous for ME/CFS 
patients (in comparison with chronic pain patients for whom the original protocol was 
developed), with a treatment duration of at least 6 months and a lower frequency than the 
common once a week-session. A hybrid treatment format with live video sessions and online 
treatment content should be investigated in future studies, especially in order to make 
treatment available for those too disabled or too distant from specialist clinics. With regards 
to the conceptualization of human suffering in ACT discussed in the Introduction, the results 
also lend preliminary support for psychological flexibility as an important mediating factor 
for improvements in disability also in ACT for ME/CFS. In a longstanding condition like 
ME/CFS, it may be more workable to: (a) analyze and interpret symptoms and experiences in 
the context of a malfunctioning sickness behavior circuitry that will not shut down even 
though it should, since; (b) the assumed inherent evolutionary functions of sickness behavior 
and derived rules there-of (“my body is telling me there is something wrong!”), which in the 
prototypical situation prompts behaviors that resolve the sickness state, does not result in 
resolution in this condition. Still, limitations such as the non-controlled design and the lack of 
competing measured constructs during treatment makes conclusions about efficacy and the 
importance of psychological flexibility very tentative, and future randomized studies with 
relevant competing factors known to affect change are needed to confirm psychological 
flexibility as a significant mediator of effects in ACT for ME/CFS, and if so, for whom.  
5.2.3 ME/CFS as a chronic sickness behavior condition – from inflammatory 
molecules to subjective experience 
Although several significant associations between inflammatory markers and symptoms were 
found in Study III, the results should be interpreted cautiously given the cross-sectional 
design and small sample size. Interestingly, biological sex moderated several associations, 
and future larger studies should include this aspect as inflammatory processes may differ in 
their relationships to symptom development between women and men in ME/CFS. Another 
aspect that could be considered both a limitation and a strength, is the measurement of 
symptoms, which could have affected the strength of the associations. Patients rated their 
average (trait) and not the present moment (state) severity of symptoms. An evident 
limitation in that levels of inflammatory markers on the day of measurement could not be 
related to the levels of symptoms as they presented at the same time-point. A strength, as 
although symptoms vary, the most commonly elevated symptoms across time should 
plausibly be related to pathophysiological mechanisms. However, cytokines in peripheral 
blood is a noisy, fluctuating variable that changes depending on a large number of other 
factors such as body mass index, smoking, recent food intake, previous night's sleep, 
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menstrual phase, and so forth. Cytokines change in circadian and ultradian rhythms - the 
same person under the same conditions will show different cytokine levels from hour to hour 
(6). Furthermore, experimental studies show that the association between inflammation and 
subjective experience does not necessarily depend on the absolute level of inflammatory 
markers, making the significant vs non-significant associations between inflammatory 
markers in periphery and subjective symptom ratings in Study III more difficult to interpret 
(85). Nevertheless, as the symptomatology in ME/CFS is analogous to a chronic sickness 
behavior state, it is plausible that illness drivers are related to a malfunctioning sickness 
behavior circuitry in a subset of patients. Longitudinal studies with multiple assessments 
including neural correlates are needed to investigate the importance of inflammatory markers 
for symptom variation in ME/CFS. Another most interesting finding, in Study IV, was that 
the level of sickness behavior assessed with the SicknessQ were similar between ME/CFS 
and chronic pain patients. Furthermore, the level of sickness behavior reported in these 
conditions is equivalent to the level reported at peak immune response in experimental 
studies (146, 153). As such, the results point to the importance of the further study of 
objective and subjective markers of sickness behavior in these groups, where malfunctioning 
sickness behavior-related mechanisms may be part of the pathophysiology in subgroups of 
patients.  
5.2.4 Concluding remarks and future directions 
For readers familiarizing themselves with ME/CFS just now, as part of reading the present 
thesis, it may seem perplexing that etiology and pathophysiological mechanisms are still 
unknown and no effective treatment choices exist, despite a considerable amount of research 
studies since the rather precise description of the condition already in the 1800’s (3). Based 
on this fact, and the results from the studies in the present thesis, I would suggest that: (a) 
ME/CFS is not ONE illness entity, but consists of several subsets of patients with 
differentiated illness mechanisms, and; (b) contextualizing ME/CFS from an ACT-based 
behavior medicine perspective and; (c) understanding it from a sickness behavior perspective 
is of evident value in order to: (d) alleviate suffering and promote quality of life; (e) guide 
further research in search of mechanisms accessible for targeted treatment, and; (f) identify 
vulnerability factors in order to develop effective preventive strategies. Most importantly, 
future research should be guided by empirically based definitions of the condition(s). As 
such, a more workable view would be to look beyond the topographical features of stressors 
(for example viral infection vs. long-term stress) or symptoms and instead consider how 
multiple “hits” on the homeostatic systems in some individuals lead to the chronic symptoms 
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seen in conditions with longstanding debilitating unclear fatigue and comorbid symptoms. 
Plausibly, it is not necessarily the type of hit in itself nor the absolute levels of immune 
mediators that cause or maintain the symptoms. Rather, research investigating ME/CFS 
should explore: (a) predictors and vulnerability factors, including biological and 
psychological/behavioral; (b) the activity and reactivity of brain areas related to interoceptive 
communication of body state; (c) the activity and reactivity of the stress and immune 
systems; (d) responses and behaviors on the psychological level; (e) how these factors are 
related and; (f) relates to disability. Such approach potentially holds the best promise of 
discovering the etiological and pathophysiological mechanisms in these conditions. In the 
wait of such discoveries, approaches effective in alleviating suffering and increasing contact 
with the valued life should be available to all sufferers. 
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